Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
13therapeutics Inc
Acepre LLC
Akaza Bioscience Ltd
Allodynic Therapeutics LLC
Apollo Therapeutics LLC
AptaTargets SL
Ayuvis Research Inc
Celestial Therapeutics Inc
Douleur Therapeutics Inc
Edesa Biotech Inc
EyeGene Inc
FasCure Therapeutics LLC
Genesen Co Ltd
Immunovo BV (Ictive)
Inimmune Corp
Kupando GmbH
Lubris Biopharma
Merck & Co Inc
Pattern Pharma Inc
Protara Therapeutics Inc
Revelation Biosciences Inc
Soin Therapeutics LLC
TaiwanJ Pharmaceuticals Co Ltd
Vascular Biogenics Ltd
Xalud Therapeutics Inc
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
(clonidine + ltrexone) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ApTOLL - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVR-48 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
Product Description
Mechanism Of Action
Biologics to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
C-34 - Drug Profile
Product Description
Mechanism Of Action
CIA-05 - Drug Profile
Product Description
Mechanism Of Action
CT-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DT-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ECF-843 - Drug Profile
Product Description
Mechanism Of Action
History of Events
G-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GS-200 - Drug Profile
Product Description
Mechanism Of Action
INI-2004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ISAS-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KUP-101 - Drug Profile
Product Description
Mechanism Of Action
ltrexone - Drug Profile
Product Description
Mechanism Of Action
History of Events
ltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
ltrexone hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
P-13 - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-7 - Drug Profile
Product Description
Mechanism Of Action
P-MAPA - Drug Profile
Product Description
Mechanism Of Action
History of Events
P2PAR-100 - Drug Profile
Product Description
Mechanism Of Action
paridiprubart - Drug Profile
Product Description
Mechanism Of Action
History of Events
PEPA-10 - Drug Profile
Product Description
Mechanism Of Action
History of Events
resatorvid - Drug Profile
Product Description
Mechanism Of Action
History of Events
REVTX-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
REVTx-99 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize TLR4 for Gastrointestil Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit TLR2 and TLR4 for Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize TLR2 and TLR4 for Pulmory Edema, Inflammation and Sepsis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize TLR4 for Chronic Obstructive Pulmory Disease, Chronic Asthma and Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to Antagonize TLR4 for Sepsis - Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to target TLR-4 for Oncology, Inflammation and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
TARA-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TJC-0133 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VB-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VB-703 - Drug Profile
Product Description
Mechanism Of Action
History of Events
XT-203 - Drug Profile
Product Description
Mechanism Of Action
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 13therapeutics Inc, 2022
Pipeline by Acepre LLC, 2022
Pipeline by Akaza Bioscience Ltd, 2022
Pipeline by Allodynic Therapeutics LLC, 2022
Pipeline by Apollo Therapeutics LLC, 2022
Pipeline by AptaTargets SL, 2022
Pipeline by Ayuvis Research Inc, 2022
Pipeline by Celestial Therapeutics Inc, 2022
Pipeline by Douleur Therapeutics Inc, 2022
Pipeline by Edesa Biotech Inc, 2022
Pipeline by EyeGene Inc, 2022
Pipeline by FasCure Therapeutics LLC, 2022
Pipeline by Genesen Co Ltd, 2022
Pipeline by Immunovo BV (Inactive), 2022
Pipeline by Inimmune Corp, 2022
Pipeline by Kupando GmbH, 2022
Pipeline by Lubris Biopharma, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Pattern Pharma Inc, 2022
Pipeline by Protara Therapeutics Inc, 2022
Pipeline by Revelation Biosciences Inc, 2022
Pipeline by Soin Therapeutics LLC, 2022
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, 2022
Pipeline by Vascular Biogenics Ltd, 2022
Pipeline by Xalud Therapeutics Inc, 2022
Dormant Products, 2022
Discontinued Products, 2022